Drug Trial Radar · NCT00359281
Pharmacokinetic Drug Interactions of AEGR-733 on Lipid-lowering Agents
Last checked: Nov 20, 2026Latest source record: Feb 23, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
125
Actual
Start
Mar 2006
Primary completion
Nov 2007
Study completion Nov 2007
Sponsor
- Lead sponsor
- Aegerion Pharmaceuticals, Inc.Industry
- Sponsor type
- Industry
- First posted
- Aug 2, 2006
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Diagnostic
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This phase II, open-label research study was conducted in 129 healthy volunteers. Each subject will be given one initial oral dose of one of 7 FDA-approved medications (probe drugs), followed by a 7 day period where subjects receive the study medication AEGR-733 at 10 or 60 mg. On study day 8 subjects will receive the second oral dose of the same probe drug that was given on day 1 and a last dose of AEGR-733 (total of 7 doses).Subjects will return in 1 week for a final safety visit. Each FDA- approved probe drug will be given to ten (10) or fifteen (15) subjects. Safety, pharmacokinetic and pharmacodynamic assessments will be performed.
Conditions
- Healthy
Interventions
atorvastatinDrug
Atrovastatin 20 mg and AEGR-733 10 mg or 60 mg
simvastatinDrug
Simvastatin 20 mg and AEGR-733 10 mg or 60 mg
ezetimibeDrug
Ezetimibe 10 mg and AEGR-733 10 mg
fenofibrateDrug
Micronized Fenofibrate 145 mg and AEGR-733 10 mg
dextromethorphanDrug
Dextromethorphan 30 mg and AEGR-733 10 mg
Extended Release NiacinDrug
1000 mg ER niacin and AEGR-733 10 mg
Primary outcomes
What the sponsor says the trial is designed to measure.
- Area Under Concentration-time Curve From 0 to Last Measureable Concentration (AUC0-t) Atorvastatin Acid (Lomitapide 10 mg)Time frame: 0 to 24 hour
- AUC0-t SimvastatinTime frame: 0 to 24 hours
- AUC0-t Simvastatin AcidTime frame: 0 to 24 hours
- AUC0-t Total EzetimibeTime frame: 0 to 24 hours
- AUC0-t Rosuvastatin (Lomitapide 10 mg)Time frame: 0 to 24 hours
- AUC0-t Fenofibric AcidTime frame: 0 to 24 hours
- AUC0-t Atorvastatin Acid (Lomitapide 60 mg)Time frame: 0 to 24 hours
- AUC0-t Rosuvastatin (Lomitapide 60 mg)Time frame: 0 to 24 hours
- AUC0-t Nicotinic AcidTime frame: 0 to 24 hours
- AUC0-t Nicotinuric AcidTime frame: 0 to 24 hours
Locations
1 site in 1 country. Site status is shown where the registry gives one.
University of Pennsylvania
Philadelphia, Pennsylvania
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.